Latest posts
-
Inside the Molecule: The Complete Peptide Atlas Mechanism Series
All five Peptide Atlas mechanisms in one place — semaglutide, tirzepatide, retatrutide, BPC-157, and GHK-Cu — with real interactive mechanism videos.
-
Ozempic Butt: What Rapid Weight Loss Does to Muscle and Tissue — and What the Research Shows
GLP-1 medications can cause significant glute and muscle atrophy. Here’s the biology behind “Ozempic butt” and what body composition and tissue repair research currently suggests about these changes.
-
Ozempic Face: What Causes It and What Skin and Collagen Research Currently Shows
Rapid fat loss from GLP-1 medications can leave facial skin hollow and lax. Here’s the biology behind “Ozempic face” — and what collagen and skin elasticity research currently shows about these changes.
-
Weight Loss Peptide Stack Research: Semaglutide, Tirzepatide, and the Next Generation of Metabolic Combinations
The progression from semaglutide (GLP-1R) to tirzepatide (GLP-1R/GIPR) to retatrutide (GLP-1R/GIPR/GCGR) represents one of pharmacology’s most productive recent research trajectories. This article examines the published evidence at each level of receptor combination, what each added target contributed to metabolic outcomes, and the key research questions the field is now investigating.
-
hGH Fragment 176-191: Examining the Research on Growth Hormone’s Lipolytic Domain
Fragment 176-191 of human growth hormone is a 16-amino acid peptide studied for its proposed role in fat metabolism. This research overview examines the structural basis for research interest in this fragment, its proposed mechanisms, preclinical findings, and its relationship to the related compound AOD-9604.
-
AOD-9604: Research on the Growth Hormone Fragment and Its Role in Metabolic Science
AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, originally developed as a research tool for studying metabolic effects independent of hGH’s growth-promoting properties. This article reviews its structural origins, proposed mechanisms, preclinical findings, and clinical development history.
-
Retatrutide: A Research Overview of the Triple Receptor Agonist and What Early Clinical Data Suggests
Retatrutide is an investigational triagonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. This research overview examines the published pharmacology, preclinical data, and early-phase clinical trial findings that have made it one of the most closely watched compounds in metabolic peptide research.
-
Tirzepatide vs Semaglutide: What Does the Published Research Actually Show?
Tirzepatide vs Semaglutide: What Does the Published Research Actually Show? Introduction: Why the Incretin Class Has Reshaped Metabolic Research For decades, incretin biology sat at the margins of metabolic science — a well-characterized but therapeutically underleveraged axis. That changed when researchers began developing synthetic analogues capable of exploiting the glucagon-like peptide-1 (GLP-1) receptor’s role in…
-
Semaglutide GLP-1 Receptor Agonist: A Research Deep Dive into the Most Studied Incretin Peptide of the Last Decade
Semaglutide GLP-1 Receptor Agonist: A Research Deep Dive into the Most Studied Incretin Peptide of the Last Decade Few peptide compounds have generated as concentrated a body of peer-reviewed literature as semaglutide. Since its characterization as a long-acting GLP-1 receptor agonist, researchers have explored its effects across metabolic, cardiovascular, and — more recently — central…
-
Weight Loss Peptides: A Research Overview
Peptide science has emerged as one of the most active frontiers in metabolic research. This overview covers GLP-1 receptor agonists, growth hormone fragment analogs, mitochondrial peptides, and other compounds under investigation for metabolic applications. For research use only.
